Massively Parallel SPR-Based Fragment Screening on Ligand Arrays Webinar
Date: Wednesday, December 11, 2024
Time: 9:00 AM PT/12:00 PM ET/18:00 CET
It’s incredible! In three days, over 125,000 interactions were measured between a panel of kinases and the Maybridge 1000 fragment library. We also profiled a kinase-focused small molecule library and obtained more than 80,000 binding interactions in a three-day instrument run.
How did we do it? Find out in this free webinar coming up December 11, 2024 to be hosted in collaboration with CarnaBio.
Kinases provide a wealth of opportunities for addressing human disease, but their presence in so many critical cellular functions creates challenges for developing drugs with the proper selectivity profiles for maximal therapeutic, and minimal toxic, effect. Direct label-free approaches, such as SPR, can complement activity assays by providing the intrinsic affinity, while observing the real-time kinetics, of interactions. In this webinar, we highlight the power of combining an extensive panel of ready-made biotinylated kinases with HT-SPR to generate a wealth of compound binding information that can augment the drug discovery process with broader selectivity profiling in less time for less cost.
What You Will Learn:
- The throughput advantages of ligand arrays
- How to get high quality SPR-data on over 100 targets simultaneously
- How to do highly parallelized fragment screening
- How we use arrays for measuring precise differences in binding behavior between ligands.
Who Should Attend:
- Lab Scientists and Decision-Makers in Small Molecule and Fragment Drug Discovery
- Biophysical Screening and Characterization Scientists
Speaker:
Anthony Giannetti, PhD, Associate Director, Applications, Carterra
Tony has more than two decades of experience in SPR, biophysics, and structural biology, specializing in fragment-based lead discovery, small molecule drug design, and platform development at Roche, Genentech, and Google[X]/Verily.